Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients With Type 2 Diabetes Treated With Once-Daily Insulin Glargine
Sponsor: Alkermes, Inc.
A PHASE3 clinical study on Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Alkermes, Inc. and has accumulated 9 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alkermes, Inc.
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alicante, Spain , Alzira, Spain , Ann Arbor, United States , Aschaffenburg, Germany , Atlanta, United States , Austin, United States , Bangalore, India , Barcelona, Spain , Berlin, Germany and 59 more locations